The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

By: Newsfile

Cranford, New Jersey--(Newsfile Corp. - August 17, 2023) - Marker Therapeutics (NASDAQ: MRKR) highlights its technology during a recently held, 75-minute Demi-Colton Virtual Salon/Webinar on cell therapy and CAR-T, a breakthrough cancer treatment that modifies a patient's own T cells to fight cancer.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • WBB Securities, an investment bank specializing in biotechnology, medical devices and life sciences, successfully organized a webinar focusing on the potential of Chimeric Antigen Receptor T-Cells (CAR-T) therapy in the future of cancer treatment.
  • The webinar, organized by CEO Steve Brozak, DMH featured distinguished speakers and experts in the field of CAR-T Cell therapy who provided insights into the science behind the therapy, its clinical applications, and potential market growth.
  • The positive response to the event underscores WBB Securities' role in connecting investors with key developments in the healthcare industry and a growing interest in CAR-T Cell therapy among the investor community.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/177588_figure1_550.jpg

Click image above to view full announcement.


WBB Securities

The WBB Research Institute is a research organization, founded by WBB Securities. The Institute focuses on emerging critical issues in healthcare that threaten to have profound impact. WBB Securities is a leading Investment Management, Investment Banking, and Equity Research firm focused on the life sciences. WBB Securities is registered with the SEC as a broker-dealer, a FINRA member firm, and a Registered Investment Advisor with a proprietary trading desk. The firm is comprised of a nationwide team of respected senior investment and research professionals serving institutional and high-net-worth clients.

Contacts:

Henry Bassman
9085229212
hbassman@wbbsec.com

Source: WBB Securities

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/177588

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.